Takeda, in collaboration with PwC, published the whitepaper “Mission: patient centricity – How technology can help achieve personalized care for rare disease patients” to showcase commitment to continuously developing its digital capabilities as one of Takeda’s top R&D priorities.
The whitepaper was developed based on an in-depth interview between Chris Easton – Takeda’s Senior Director & Global Commercial Lead, Personalized Health & Innovation, Rare Hematology – and Chris Isler – Senior Executive Advisor at PwC. They discussed innovation, data and technology and how
each can be applied to the rare disease space, a segment of the health industry that has been comparatively lagging behind other highly prevalent therapeutic areas.
Addressing misconceptions around functionality and reaffirming Takeda’s patient-centric approach, this whitepaper is a statement of intent and ambition for the rare disease patient community. It also highlights Takeda’s commitment to continuously developing its digital capabilities in tandem with the resource that goes into research and development within the rare disease space.
To download and read the whitepaper, click here.